Click to view our statement on Accessibility
Back

Examining the Risks and Benefits of IPO Alternatives: Direct Listings & SPACS

30 April 2021

Author(s)

Louis Lehot headshot.

Louis Lehot

Partner

Silicon Valley 650.251.1222

Related Insights

View All Posts
20 December 2024 Health Care Law Today

GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.
20 December 2024 Manufacturing Industry Advisor

Christmas Came Early: Justice Delivered in Supplier Dispute Over Unjust Enrichment

The AirBoss saga continues… This holiday season, AirBoss Flexible Products Co. received a monumental legal victory, righting a costly wrong in MSSC, Inc. v. AirBoss.
19 December 2024 Health Care Law Today

HIPAA Reproductive Health Care Amendments: Compliance in an Uncertain Enforcement Landscape

The amendments to the HIPAA Privacy Rule designed to protect reproductive health care information are under legal challenge as the compliance date quickly approaches.